Table 5. Baseline clinical characteristics and outcomes (groups defined using relative volume change criteria).
| Stable Hematoma | Hematoma Retraction | Hematoma Expansion | P value | |
|---|---|---|---|---|
| HS, N = 90 | HR, N = 8 | HE, N = 38 | ||
| Baseline | ||||
| Age; Mean ± SD (years) | 69 ± 13 | 67 ± 14 | 71 ± 15 | 0.315 |
| Male | 50 (55%) | 6 (75%) | 23 (61%) | 0.530 |
| NIHSS, Median (IQR) | 10 (8, 16) | 11 (10, 13) | 14 (10, 18)a | 0.197 |
| Baseline Systolic BP (mmHg); Median (IQR) | 178.3 (159, 199) | 173.0 (148.5, 188.3) | 183 (158, 200) | 0.600 |
| Baseline Diastolic BP (mmHg); Median (IQR) | 90.50 (82, 106) | 87.50 (80.75, 110) | 88 (76.5, 110) | 0.801 |
| Past History of Stroke | 19 (21.6%) | 1 (12.5%) | 5 (13.2%) | 0.483 |
| Anticoagulant-associated ICH | 5 (6.1%) | 2 (28.6%) | 8 (22.9%)a | 0.015 |
| Diabetes | 24 (27.6%) | 2 (25%) | 10 (26.3%) | 0.980 |
| Glucose (mmol/l), Median (IQR) | 7.15 (5.75, 8.35) | 6.65 (6.25, 7.75) | 7.55 (5.85, 8.95) | 0.610 |
| Hypertension | 67 (76.1%) | 6 (75%) | 28 (73.7%) | 0.958 |
| Aspirin | 17 (21%) | 2 (28.6%) | 6 (18.2%) | 0.820 |
| Outcome | ||||
| 90 Day mRS | 3 (2, 5) | 3 (3, 4) | 5 (3, 6)b | 0.003 |
| mRS 0–2 | 30 (50.8%) | 4 (66.7%) | 7 (24.1%)a | 0.030 |
avs. HS p<0.025
bvs. HS and HR p<0.029